Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Metabolic rewiring beyond Warburg in chronic lymphocytic leukemia: How much do we actually know?

Galicia-Vázquez G, Aloyz R.

Crit Rev Oncol Hematol. 2019 Feb;134:65-70. doi: 10.1016/j.critrevonc.2018.12.003. Epub 2018 Dec 19. Review.

2.

Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes.

Galicia-Vázquez G, Aloyz R.

Front Oncol. 2018 Sep 26;8:411. doi: 10.3389/fonc.2018.00411. eCollection 2018.

3.

PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines.

Sharif-Askari B, Amrein L, Aloyz R, Panasci L.

Breast Cancer Res Treat. 2018 Nov;172(1):23-32. doi: 10.1007/s10549-018-4888-6. Epub 2018 Jul 23.

PMID:
30039287
4.

Del11q-positive CLL lymphocytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition.

Galicia-Vázquez G, Smith S, Aloyz R.

Blood Cancer J. 2018 Jan 24;8(1):13. doi: 10.1038/s41408-017-0039-2. No abstract available.

5.

A 12-gene signature to distinguish colon cancer patients with better clinical outcome following treatment with 5-fluorouracil or FOLFIRI.

Paquet ER, Cui J, Davidson D, Pietrosemoli N, Hassan HH, Tsofack SP, Maltais A, Hallett MT, Delorenzi M, Batist G, Aloyz R, Lebel M.

J Pathol Clin Res. 2015 Apr 9;1(3):160-72. doi: 10.1002/cjp2.17. eCollection 2015 Jul.

6.

Adaptive metabolic rewiring to chronic SFK inhibition.

Pinedo-Carpio E, Davidson D, Martinez Marignac VL, Panasci J, Aloyz R.

Oncotarget. 2016 Mar 17;8(40):66758-66768. doi: 10.18632/oncotarget.8146. eCollection 2017 Sep 15.

7.

Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan.

Abu-Sanad A, Wang Y, Hasheminasab F, Panasci J, Noë A, Rosca L, Davidson D, Amrein L, Sharif-Askari B, Aloyz R, Panasci L.

Front Pharmacol. 2015 Jul 22;6:147. doi: 10.3389/fphar.2015.00147. eCollection 2015.

8.

Effects of dna-dependent protein kinase inhibition by NU7026 on dna repair and cell survival in irradiated gastric cancer cell line N87.

Niazi MT, Mok G, Heravi M, Lee L, Vuong T, Aloyz R, Panasci L, Muanza T.

Curr Oncol. 2014 Apr;21(2):91-6. doi: 10.3747/co.21.1509.

9.

Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming.

Martinez Marignac VL, Smith S, Toban N, Bazile M, Aloyz R.

Oncotarget. 2013 Dec;4(12):2550-66.

10.

Pharmacological targeting of eIF4E in primary CLL lymphocytes.

Martinez-Marignac V, Shawi M, Pinedo-Carpio E, Wang X, Panasci L, Miller W, Pettersson F, Aloyz R.

Blood Cancer J. 2013 Sep 13;3:e146. doi: 10.1038/bcj.2013.43. No abstract available.

11.

Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes.

Shawi M, Chu TW, Martinez-Marignac V, Yu Y, Gryaznov SM, Johnston JB, Lees-Miller SP, Assouline SE, Autexier C, Aloyz R.

PLoS One. 2013 Jul 29;8(7):e70428. doi: 10.1371/journal.pone.0070428. Print 2013.

12.

Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond.

Davidson D, Amrein L, Panasci L, Aloyz R.

Front Pharmacol. 2013 Jan 31;4:5. doi: 10.3389/fphar.2013.00005. eCollection 2013.

13.

Heterozygous mutations in the PALB2 hereditary breast cancer predisposition gene impact on the three-dimensional nuclear organization of patient-derived cell lines.

Wark L, Novak D, Sabbaghian N, Amrein L, Jangamreddy JR, Cheang M, Pouchet C, Aloyz R, Foulkes WD, Mai S, Tischkowitz M.

Genes Chromosomes Cancer. 2013 May;52(5):480-94. doi: 10.1002/gcc.22045. Epub 2013 Jan 23.

PMID:
23341105
14.

The phosphatidylinositol-3 kinase I inhibitor BKM120 induces cell death in B-chronic lymphocytic leukemia cells in vitro.

Amrein L, Shawi M, Grenier J, Aloyz R, Panasci L.

Int J Cancer. 2013 Jul;133(1):247-52. doi: 10.1002/ijc.27989. Epub 2013 Jan 15.

15.

The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.

Davidson D, Wang Y, Aloyz R, Panasci L.

Invest New Drugs. 2013 Apr;31(2):461-8. doi: 10.1007/s10637-012-9886-7. Epub 2012 Oct 9.

16.

Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score.

Sahebjam S, Aloyz R, Pilavdzic D, Brisson ML, Ferrario C, Bouganim N, Cohen V, Miller WH Jr, Panasci LC.

Br J Cancer. 2011 Oct 25;105(9):1342-5. doi: 10.1038/bjc.2011.402. Epub 2011 Oct 4.

17.

Response of concomitant chronic myelogenous leukemia and chronic lymphocytic leukemia to imatinib mesylate.

Yoon JY, Kumar R, Aloyz R, Johnston JB.

Leuk Res. 2011 Sep;35(9):e179-80. doi: 10.1016/j.leukres.2011.06.007. Epub 2011 Jul 28. No abstract available.

PMID:
21802141
18.

ZRF4, a combi-molecule with increased efficacy as compared with the individual components in chronic lymphocytic leukemia lymphocytes in vitro.

Amrein L, Rachid Z, Jean-Claude B, Soulières D, Aloyz R, Panasci L.

Leukemia. 2011 Sep;25(9):1512-6. doi: 10.1038/leu.2011.110. Epub 2011 Jun 7. No abstract available.

19.

Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells.

Davidson D, Grenier J, Martinez-Marignac V, Amrein L, Shawi M, Tokars M, Aloyz R, Panasci L.

Invest New Drugs. 2012 Aug;30(4):1736-42. doi: 10.1007/s10637-011-9678-5. Epub 2011 May 13.

PMID:
21567185
20.

Trastuzumab and vinorelbine in early stages of HER2-positive breast cancer.

Ferrario C, Wong A, Gao T, Bouganim N, Aloyz R, Panasci LC.

J Chemother. 2011 Feb;23(1):32-5.

PMID:
21482492
21.

The effect of a DNA repair gene on cellular invasiveness: XRCC3 over-expression in breast cancer cells.

Martinez-Marignac VL, Rodrigue A, Davidson D, Couillard M, Al-Moustafa AE, Abramovitz M, Foulkes WD, Masson JY, Aloyz R.

PLoS One. 2011 Jan 24;6(1):e16394. doi: 10.1371/journal.pone.0016394.

22.

Dual inhibition of the homologous recombinational repair and the nonhomologous end-joining repair pathways in chronic lymphocytic leukemia therapy.

Amrein L, Davidson D, Shawi M, Petruccelli LA, Miller WH Jr, Aloyz R, Panasci L.

Leuk Res. 2011 Aug;35(8):1080-6. doi: 10.1016/j.leukres.2011.01.004. Epub 2011 Feb 1.

PMID:
21281966
23.

Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells.

Davidson D, Coulombe Y, Martinez-Marignac VL, Amrein L, Grenier J, Hodkinson K, Masson JY, Aloyz R, Panasci L.

Invest New Drugs. 2012 Jun;30(3):1248-56. doi: 10.1007/s10637-010-9626-9. Epub 2011 Jan 11.

PMID:
21221710
24.

A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients.

Hebb J, Assouline S, Rousseau C, Desjardins P, Caplan S, Egorin MJ, Amrein L, Aloyz R, Panasci L.

Cancer Chemother Pharmacol. 2011 Sep;68(3):643-51. doi: 10.1007/s00280-010-1530-7. Epub 2010 Dec 1.

PMID:
21120481
25.

Magnetotactic bacteria penetration into multicellular tumor spheroids for targeted therapy.

Mokrani N, Felfoul O, Afkhami Zarreh F, Mohammadi M, Aloyz R, Batist G, Martel S.

Conf Proc IEEE Eng Med Biol Soc. 2010;2010:4371-4. doi: 10.1109/IEMBS.2010.5627105.

PMID:
21096454
26.

p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes.

Amrein L, Soulières D, Johnston JB, Aloyz R.

Leuk Res. 2011 Jan;35(1):99-102. doi: 10.1016/j.leukres.2010.05.029. Epub 2010 Jun 22.

PMID:
20573397
27.

Vav-1 expression correlates with NFκB activation and CD40-mediated cell death in diffuse large B-cell lymphoma cell lines.

Hollmann A, Aloyz R, Baker K, Dirnhofer S, Owens T, Sladek R, Tzankov A.

Hematol Oncol. 2010 Sep;28(3):142-50. doi: 10.1002/hon.935.

PMID:
20155735
28.

Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma.

Hollmann CA, Tzankov A, Martínez-Marignac VL, Baker K, Grygorczyk C, Grygorczyk R, Foulkes W, Nadeau J, Dirnhofer S, Aloyz R.

Leuk Res. 2010 May;34(5):585-93. doi: 10.1016/j.leukres.2009.08.030. Epub 2009 Sep 16.

PMID:
19758698
29.

Primary del 17 chronic lymphocytic leukaemia lymphocytes are hypersensitive to dasatinib in vitro.

Amrein L, Panasci L, Gibson SB, Johnston JB, Soulières D, Aloyz R.

Br J Haematol. 2009 Nov;147(3):396-8. doi: 10.1111/j.1365-2141.2009.07814.x. Epub 2009 Sep 2. No abstract available.

30.

Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer.

Ferrario C, Davidson A, Bouganim N, Aloyz R, Panasci LC.

Ann Oncol. 2009 Apr;20(4):792-5. doi: 10.1093/annonc/mdp019. Epub 2009 Feb 17. No abstract available.

PMID:
19223574
31.

BRCA1 mutations contribute to cell motility and invasion by affecting its main regulators.

Yasmeen A, Liu W, Dekhil H, Kassab A, Aloyz R, Foulkes WD, Al Moustafa AE.

Cell Cycle. 2008 Dec;7(23):3781-3. No abstract available.

PMID:
19098453
32.

Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro.

Amrein L, Hernandez TA, Ferrario C, Johnston J, Gibson SB, Panasci L, Aloyz R.

Br J Haematol. 2008 Dec;143(5):698-706. doi: 10.1111/j.1365-2141.2008.07418.x .

PMID:
19062342
33.

Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer.

Tischkowitz MD, Yilmaz A, Chen LQ, Karyadi DM, Novak D, Kirchhoff T, Hamel N, Tavtigian SV, Kolb S, Bismar TA, Aloyz R, Nelson PS, Hood L, Narod SA, White KA, Ostrander EA, Isaacs WB, Offit K, Cooney KA, Stanford JL, Foulkes WD.

Cancer Lett. 2008 Oct 18;270(1):173-80. doi: 10.1016/j.canlet.2008.05.006. Epub 2008 Jun 20.

34.

XRCC3 depletion induces spontaneous DNA breaks and p53-dependent cell death.

Loignon M, Amrein L, Dunn M, Aloyz R.

Cell Cycle. 2007 Mar 1;6(5):606-11. Epub 2007 Mar 30.

PMID:
17351336
35.
36.

Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia.

Césaire R, Olière S, Sharif-Askari E, Loignon M, Lézin A, Olindo S, Panelatti G, Kazanji M, Aloyz R, Panasci L, Bell JC, Hiscott J.

Oncogene. 2006 Jan 19;25(3):349-58.

PMID:
16186807
37.

Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis.

Xu ZY, Loignon M, Han FY, Panasci L, Aloyz R.

J Pharmacol Exp Ther. 2005 Aug;314(2):495-505. Epub 2005 Apr 20.

PMID:
15843498
38.

Imatinib sensitizes CLL lymphocytes to chlorambucil.

Aloyz R, Grzywacz K, Xu ZY, Loignon M, Alaoui-Jamali MA, Panasci L.

Leukemia. 2004 Mar;18(3):409-14.

PMID:
14712290
39.

Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects.

Saarelainen T, Hendolin P, Lucas G, Koponen E, Sairanen M, MacDonald E, Agerman K, Haapasalo A, Nawa H, Aloyz R, Ernfors P, Castrén E.

J Neurosci. 2003 Jan 1;23(1):349-57.

40.

Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD.

Aloyz R, Xu ZY, Bello V, Bergeron J, Han FY, Yan Y, Malapetsa A, Alaoui-Jamali MA, Duncan AM, Panasci L.

Cancer Res. 2002 Oct 1;62(19):5457-62.

41.

DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program.

Xu Z, Chen ZP, Malapetsa A, Alaoui-Jamali M, Bergeron J, Monks A, Myers TG, Mohr G, Sausville EA, Scudiero DA, Aloyz R, Panasci LC.

Anticancer Drugs. 2002 Jun;13(5):511-9.

PMID:
12045463
42.

Homologous recombinational repair vis-à-vis chlorambucil resistance in chronic lymphocytic leukemia.

Bello VE, Aloyz RS, Christodoulopoulos G, Panasci LC.

Biochem Pharmacol. 2002 May 1;63(9):1585-8.

PMID:
12007561
43.

The role of DNA repair in nitrogen mustard drug resistance.

Panasci L, Xu ZY, Bello V, Aloyz R.

Anticancer Drugs. 2002 Mar;13(3):211-20. Review.

PMID:
11984064
44.

TrkA mediates developmental sympathetic neuron survival in vivo by silencing an ongoing p75NTR-mediated death signal.

Majdan M, Walsh GS, Aloyz R, Miller FD.

J Cell Biol. 2001 Dec 24;155(7):1275-85. Epub 2001 Dec 24.

45.

In vitro evidence for homologous recombinational repair in resistance to melphalan.

Wang ZM, Chen ZP, Xu ZY, Christodoulopoulos G, Bello V, Mohr G, Aloyz R, Panasci LC.

J Natl Cancer Inst. 2001 Oct 3;93(19):1473-8.

PMID:
11584063
46.

Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair.

Panasci L, Paiement JP, Christodoulopoulos G, Belenkov A, Malapetsa A, Aloyz R.

Clin Cancer Res. 2001 Mar;7(3):454-61. Review.

47.

Evidence that helix-loop-helix proteins collaborate with retinoblastoma tumor suppressor protein to regulate cortical neurogenesis.

Toma JG, El-Bizri H, Barnabe-Heider F, Aloyz R, Miller FD.

J Neurosci. 2000 Oct 15;20(20):7648-56.

48.

Ras regulates sympathetic neuron survival by suppressing the p53-mediated cell death pathway.

Mazzoni IE, Saïd FA, Aloyz R, Miller FD, Kaplan D.

J Neurosci. 1999 Nov 15;19(22):9716-27.

49.

Activity-dependent activation of TrkB neurotrophin receptors in the adult CNS.

Aloyz R, Fawcett JP, Kaplan DR, Murphy RA, Miller FD.

Learn Mem. 1999 May-Jun;6(3):216-31.

50.

Supplemental Content

Support Center